文献速递儿科与产科急症

分娩硬膜外镇痛、催产素暴露与儿童自闭症谱系障碍风险的关联

Association of Labor Epidural Analgesia, Oxytocin Exposure, and Risk of Autism Spectrum Disorders in Children.
PubMed 文献 · JAMA Netw Open · 2023-07-03
一句话结论队列研究提示母亲分娩硬膜外镇痛与儿童自闭症谱系障碍风险相关(HR 1.28),同时使用催产素时风险进一步升高(HR 1.30)。

该队列研究纳入2008至2017年南加州单一整合医疗系统内205 994例阴道分娩单胎,随访至2021年12月31日。随访期间5146名儿童(2.5%)诊断为自闭症谱系障碍。调整协变量后,硬膜外镇痛与自闭症谱系障碍风险的关联独立于催产素暴露(HR 1.28;95%CI 1.18-1.38);催产素暴露调整硬膜外镇痛后关联不显著(HR 1.05;95%CI 0.99-1.12)。两者存在显著交互作用(交互P=0.02),与无暴露相比,仅硬膜外镇痛HR 1.20(95%CI 1.09-1.32),两者均用HR 1.30(95%CI 1.20-1.42),仅催产素HR 0.90(95%CI 0.78-1.04)。作者认为需谨慎解读,需进一步研究重复或反驳结果并检验生物学合理性。

要点

  • 在205 994例阴道分娩单胎中,随访期间5146名儿童(2.5%)诊断为自闭症谱系障碍。
  • 调整协变量后,硬膜外镇痛与自闭症谱系障碍风险独立相关(HR 1.28;95%CI 1.18-1.38)。
  • 催产素暴露调整硬膜外镇痛后与自闭症谱系障碍风险关联不显著(HR 1.05;95%CI 0.99-1.12)。
  • 硬膜外镇痛与催产素对儿童自闭症谱系障碍风险存在显著交互作用(交互P=0.02)。
  • 与无暴露相比,仅硬膜外镇痛HR 1.20(95%CI 1.09-1.32),两者均用HR 1.30(95%CI 1.20-1.42),仅催产素HR 0.90(95%CI 0.78-1.04)。

适用人群与场景

  • 2008至2017年南加州单一整合医疗系统内阴道分娩的单胎妊娠,共205 994例;儿童随访至2021年12月31日。

研究设计与关键结果

  • 研究类型为队列研究,纳入205 994例阴道分娩单胎,来自南加州单一整合医疗系统,2008至2017年出生,随访至2021年12月31日。
  • 暴露:分娩硬膜外镇痛和/或催产素使用;主要结局:随访期间儿童临床诊断为自闭症谱系障碍及诊断年龄。
  • 队列中153 880名儿童(74.7%)暴露于硬膜外镇痛,117 808名儿童(57.2%)暴露于催产素;儿童性别约半数为男孩半数为女孩。
  • 母亲中位(IQR)年龄:未暴露硬膜外镇痛30.8(26.8-34.5)岁,暴露硬膜外镇痛30.0(25.9-33.8)岁,未暴露催产素30.4(26.5-34.1)岁,暴露催产素30.0(25.9-33.9)岁。
  • 随访期间5146名儿童(2.5%)诊断为自闭症谱系障碍;硬膜外镇痛暴露组中催产素暴露比例(67.7%)高于未暴露组(26.1%)。
  • 硬膜外镇痛与自闭症谱系障碍风险的关联独立于催产素暴露(HR 1.28;95%CI 1.18-1.38);催产素暴露调整硬膜外镇痛后关联不显著(HR 1.05;95%CI 0.99-1.12)。
  • 硬膜外镇痛与催产素对儿童自闭症谱系障碍风险存在显著交互作用(交互P=0.02);与无暴露相比,仅硬膜外镇痛HR 1.20(95%CI 1.09-1.32),两者均用HR 1.30(95%CI 1.20-1.42),仅催产素HR 0.90(95%CI 0.78-1.04)。

证据类型、等级与局限

  • 证据类型:队列研究。
  • 作者结论:研究结果提示母亲硬膜外镇痛与儿童自闭症谱系障碍风险存在关联,若同时给予催产素风险似乎进一步升高;无硬膜外镇痛的催产素暴露与儿童自闭症谱系障碍风险无关;这些发现必须谨慎解读。
  • 局限:原文未报告局限性;作者指出需进一步研究以重复或反驳该研究结果并检验生物学合理性。

对床旁实践的改变

  • 作者认为研究结果提示母亲硬膜外镇痛与儿童自闭症谱系障碍风险存在关联,同时使用催产素时风险似乎进一步升高,但必须谨慎解读。
  • 作者指出需进一步研究以重复或反驳该研究结果并检验生物学合理性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

IMPORTANCE: Maternal labor epidural analgesia (LEA) and oxytocin use for labor and delivery have been reported to be associated with child autism spectrum disorders (ASD). However, it remains unclear whether these 2 common medications used during labor and delivery have synergistic associations with ASD risk in children.

OBJECTIVE: To assess the independent associations of LEA and oxytocin during labor and delivery with ASD, as well as outcome modification associated with the concurrent use of both interventions.

DESIGN, SETTING, AND PARTICIPANTS: Data for this cohort study included 205 994 singleton births with vaginal deliveries in a single integrated health care system in Southern California from calendar years 2008 to 2017. Children were followed up to December 31, 2021. Data on use of LEA and oxytocin, covariates, and ASD outcome in children were obtained from electronic medical records. Cox proportional hazards regression was used to estimate the hazard ratios (HRs) adjusting for covariates.

EXPOSURES: Labor epidural analgesia and/or oxytocin use during labor and delivery.

MAIN OUTCOMES AND MEASURES: A child's clinical diagnosis of ASD during follow-up and at age of diagnosis.

RESULTS: Among the cohort, 153 880 children (74.7%) were exposed to maternal LEA and 117 808 children (57.2%) were exposed to oxytocin during labor and delivery. The population of children was approximately half boys and half girls. The median (IQR) age of the mothers was 30.8 (26.8-34.5) years for those not exposed to LEA, 30.0 (25.9-33.8) years for those exposed to LEA, 30.4 (26.5-34.1) years for those unexposed to oxytocin, and 30.0 (25.9-33.9) years for those exposed to oxytocin during labor and delivery. A total of 5146 children (2.5%) had ASD diagnosed during follow-up. Oxytocin exposure was higher among LEA-exposed (67.7%) than -unexposed (26.1%) children. The ASD risk associated with LEA was independent of oxytocin exposure (HR, 1.28; 95% CI, 1.18-1.38); however, the ASD risk associated with oxytocin was not significant after adjusting for LEA exposure (HR, 1.05; 95% CI, 0.99-1.12). A significant interaction of LEA and oxytocin on child ASD risk was found (P = .02 for interaction). Compared with no exposure, HRs were 1.20 (95% CI, 1.09-1.32) for LEA alone, 1.30 (95% CI, 1.20-1.42) for both LEA and oxytocin, and 0.90 (95% CI, 0.78-1.04) for oxytocin alone.

CONCLUSIONS AND RELEVANCE: The findings of this cohort study suggest an association between maternal LEA and ASD risk in children, and the risk appeared to be further increased if oxytocin was also administered. Oxytocin exposure without LEA exposure was not associated with ASD risk in children. These findings must be interpreted with caution. Further studies are needed to replicate or refute the study results and examine biological plausibility.

来源:JAMA Netw Open,查看原文。版权归原作者所有。

参考来源

  1. Qiu C, Carter SA, Lin JC, et al. Association of Labor Epidural Analgesia, Oxytocin Exposure, and Risk of Autism Spectrum Disorders in Children. JAMA Netw Open. 2023. PMID: 37477919. doi:10.1001/jamanetworkopen.2023.24630

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。